← Oncology Approval Tracker

FDA DECISION ·

Prevymis

letermovir · Merck

FDA approvalNew or expanded indicationCytomegalovirus prevention after stem cell transplant
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Prevention of cytomegalovirus infection and disease in CMV-seropositive allogeneic hematopoietic stem cell transplant recipients aged 6 months and older and weighing at least 6 kg.

LAMPGEN ANALYSIS

Why it matters

The expansion added an approved prevention option for younger transplant recipients, including those receiving transplants for blood cancers.

What research teams should watch

Capture CMV serostatus, age, weight and cyclosporine use; keep prophylaxis and virologic surveillance timelines aligned.

PRIMARY RECORDS

Sources